Retatrutide

Description

Notably:

• A Phase 2 clinical trial published in the New England Journal of Medicine (2023) evaluated retatrutide in adults with obesity and reported significant reductions in body weight across study arms.
• The study was led by Ania Jastreboff, examining multi-receptor agonism as a novel metabolic approach.
• Retatrutide has been developed and studied by Eli Lilly and Company in controlled clinical environments.

These publications highlight growing scientific interest in triple-pathway receptor activity within metabolic research.

(References available upon request for laboratory review.)

Why Researchers Select GLP-3 Retatrutide

• Triple receptor targeting (GLP-1 / GIP / Glucagon pathways)
• Investigated in metabolic and body-weight research models
• Explored for appetite signaling and energy regulation mechanisms
• Extended activity profile observed in research settings
• Frequently referenced in structured, long-interval study designs

Product Specifications

• >99% purity – independently lab tested
• Supplied as high-purity lyophilized powder
• Requires reconstitution prior to laboratory use
• Bacteriostatic water required for mixing (sold separately)
• Swirl gently to dissolve — do not shake
• Ensure complete dissolution before handling

Storage & Stability

• Store lyophilized vial in freezer conditions until use
• Maintain 2–8°C and protect from light
• Refrigerate after reconstitution
• Utilize within standard laboratory handling timelines

Research Use Notice

This product is intended strictly for laboratory research purposes only. Not for human consumption, therapeutic use, or veterinary application.